Alerta

ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF

Resumen de: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

5-CYANO-1H-IMIDAZOLE-2-CARBOXAMIDE COMPOUNDS AS CSF1R INHIBITORS

Resumen de: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF

Resumen de: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF

Resumen de: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

Sel de fumarate de 1-(4-amino-5-chloro-2-méthoxyphényl)-3-1-(cycloheptylméthyl)-4-pipéridinylpropan-1-one –Composition pharmaceutique et utilisation associées

Resumen de: FR3166146A1

Sel de fumarate de 1-(4-amino-5-chloro-2-méthoxyphényl)-3-1-(cycloheptylméthyl)-4-pipéridinylpropan-1-one – Composition pharmaceutique et utilisation associées La présente invention concerne un composé choisi parmi le sel de fumarate de 1-(4-amino-5-chloro-2-méthoxyphényl)-3-1-(cycloheptylméthyl)-4-pipéridinylpropan-1-one, et les hydrates de ce sel, ledit composé étant notamment à l’état de solide cristallin. La présente invention concerne également une composition pharmaceutique, comprenant en tant qu’ingrédient pharmaceuticalement actif, le composé de l’invention ainsi que le composé de l’invention pour son utilisation en tant que médicament et en particulier pour son utilisation dans le traitement d’une maladie neurodégénérative choisie en particulier parmi la maladie d’Alzheimer et la maladie de Parkinson. Figure pour l’abrégé : Néant

STABILIZED CIRCULATING PEPTIDES AND USES THEREOF

Resumen de: WO2026055173A1

The present invention provides a method for identifying a subject having a stabilized circulating peptide. The method comprises detecting the stabilized circulating peptide in a body fluid sample, for example, a serum or plasma sample, from the subject. The method may further comprise treating a neurodegenerative disease, or monitoring or adjusting a treatment of a neurodegenerative disease. Also provided is a kit. The kit comprises a binding protein that specifically binds a stabilized circulating peptide in a body fluid sample, for example, a serum or plasma sample, from a subject. The kit may further comprise an agent for detecting, treating or monitoring a neurodegenerative disease in the subject. The neurodegenerative disease may be Alzheimer disease.

USE OF C9ORF72 -MEDIATED GENES FOR DIAGNOSIS AND TREATMENT OF NEURONAL DISEASES

Resumen de: US20260071275A1

The present disclosure provides compositions and methods using C9ORF72-mediated genes and expression products thereof for diagnosis, treatment and prevention of amyotrophic lateral sclerosis, frontotemporal dementia, or both, in carriers of a C9ORF72 hexanucleotide expansion. The present invention also relates to a method of identifying therapeutic agents to treat and diagnose amyotrophic lateral sclerosis, frontotemporal dementia, or both, in carriers of a C9ORF72 hexanucleotide expansion based on C9ORF72-mediated genes.

FORMULATION OF GLIBENCLAMIDE AND LOW-DOSE METFORMIN FOR THE PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES

Resumen de: WO2026052795A1

The present invention provides a formulation of metformin and glibenclamide for the prevention and/or treatment of neurodegenerative diseases, preferably chosen among Parkinson's disease, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal dementia, Lewy body dementia, Huntington's disease and Alzheimer's disease.

MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88

Resumen de: WO2026055419A1

N-(1,1'-biaryl-4-yl)-N-((1-hydroxycycloalkyl)methyl)-2-(aryl)cyclopropane-1-carboxamide compounds (I) and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, tardive dyskinesia, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and/or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease, basal ganglia disorders, and tardive dyskinesia.

CARBAZOLE DERIVATIVE AND USE THEREOF

Resumen de: WO2026052031A1

The present invention belongs to the technical field of medicine. Disclosed are a pyranocarbazole derivative and a preparation method therefor, and a pharmaceutical composition thereof and the use thereof. Specifically, disclosed in the present invention are pyranocarbazole derivatives as represented by general formulas I and II. The derivative is prepared by means of artificial synthesis. Further disclosed are a pharmaceutical composition containing the derivative, and the use thereof in resisting inflammation, resisting ischemic cerebral injury, relieving pain, resisting brain trauma, treating post-stroke depression, treating vascular dementia and cerebral small vessel disease, resisting Alzheimer's disease, and treating amyotrophic lateral sclerosis.

DEVELOPMENT AND USE OF THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE

Resumen de: AU2024334698A1

Provided is an antibody that binds to β-amyloid (Aβ), or an antigen-binding fragment thereof. Further provided are a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a cell comprising the antibody or the antigen-binding fragment or nucleic acid thereof, a pharmaceutical composition, a kit, and the use of the antibody or the antigen-binding fragment thereof in the preparation of a drug used for treating or preventing a disease caused by abnormal accumulation or deposition of Aβ in subjects.

METHODS AND COMPOSITIONS OF DOPAMINERGIC CELLS FOR TREATING PARKINSON'S DISEASE

Resumen de: AU2024335242A1

This disclosure relates to methods and compositions for the treatment of Parkinson's disease, a neurodegenerative disorder characterized by a loss of dopaminergic neurons. In particular, this disclosure provides formulations of dopaminergic cells demonstrated to possess a therapeutic impact on both motor and non-motor symptoms of the disease.

Antibodies binding to citrullinated histone 2A and/or 4

Resumen de: AU2026201302A1

The invention provides antibodies or binding fragments thereof directed against citrulline­ containing epitopes. The antibodies or binding fragments thereof of the invention can be 5 used in therapy, for example in the treatment or prevention ofNeutrophil Extracellular Trap (NET)-associated pathologies. The antibodies or binding fragments thereof of the invention can be used in the treatment or prevention of NET-associated pathologies such as systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune 10 hepatitis, juvenile idiopathic arthritis, Sjogren' s disease, Anti-phospholipid Syndrome, Bechet's disease, spondylitis, spondyloarthropathy, multiple system atrophy, Parkinson's disease, Lewy body dementia asthma, allergic rhinovirus exacerbated asthma, allergic asthma, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, dry eye disease, uveitis, nongranulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, 15 bronchitis, or other NET-associated pathologies such as wound healing in diabetes, cancer, cancer metastasis, and transplant organ health in vivo or ex vivo. The invention also provides pharmaceutical compositions and methods for treating or preventing NET­ associated pathologies such as SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune

ANTI-CD2 ANTIBODIES FOR AMYOTROPHIC LATERAL SCLEROSIS

Resumen de: WO2026052700A1

Provided herein is an anti-CD2 antibody or antigen binding fragment thereof for treating and/or preventing ALS in a subject in need thereof.

METHOD OF TREATING ALZHEIMER'S DISEASE USING ANTI-N3pGlu AMYLOID BETA ANTIBODIES

Resumen de: WO2026055601A1

The invention pertains to a method for reducing amyloid plaques in the brain of a human suffering from a disease characterized by Aβ plaques in the brain. It also concerns the treatment or prevention of diseases characterized by Aβ deposition in the brain, such as Alzheimer's disease, Alzheimer's disease in Down syndrome, and cerebral amyloid angiopathy. Certain aspects of the invention involve methods, doses, or dosing regimens that decrease the risk, frequency, severity, or occurrence of amyloid-related imaging abnormalities (ARIA) in subjects undergoing the described treatments. These aspects ensure that while reducing ARIA-related issues, the methods still effectively remove amyloid β plaques from the subject's brain. Additionally, the methods, doses, or dosing regimens disclosed herein aim to reduce ARIA risks, frequency, severity, or events, in human subjects with one or two alleles of APOE4.

BIOMARKERS FOR DETECTING AND/OR DETERMINING A TREATMENT REGIMEN FOR ALZHEIMER'S DISEASE

Resumen de: US20260072043A1

The present disclosure provides methods for diagnosing or determining susceptibility to Alzheimer's Disease a subject by obtaining a biological sample from the subject; detecting one or more biomarkers in the biological sample selected from the group consisting of: inflammation biomarkers, oxidative stress biomarkers, insulin resistance biomarkers, and autophagy biomarkers; and diagnosing the subject with Alzheimer's Disease where one or more of the biomarkers is detected in the biological sample. Also provided are methods of treating a subject with Alzheimer's Disease comprising administering to the subject an effective amount of one or more agents for the treatment of inflammation, oxidative stress, insulin resistance, and/or autophagy.

PREVENTIVE OR THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASE

Resumen de: EP4706655A1

The purpose of the present invention is to provide a medicinal agent that exhibits the effect of inhibiting aggregation of a causative protein of an HRE-related neurodegenerative disease such as ALS. According to the present invention, rifampicin or a rifampicin compound selected from the group consisting of rifampicin, a derivative thereof, and a salt of rifampicin or the derivative and/or resveratrol or a resveratrol compound selected from the group consisting of resveratrol and a derivative thereof is an active ingredient of a preventive or therapeutic agent for a neurodegenerative disease caused by TDP-43 accumulation, or an active ingredient of a preventive or therapeutic agent for ALS.

TREATMENT OF ALZHEIMER'S DISEASE

Resumen de: WO2024229414A2

Neurodegenerative diseases are treated by the co-administration to a subject of an effective amount of a stilbene, a flavonol, and a TLR4/MD2 receptor antagonist. A preferred stilbene is resveratrol, a preferred flavonol is quercetin, and a preferred TLR4/MD2 receptor antagonist is curcumin.

Compounds

Resumen de: GB2700773A

A compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein Ring A is selected from: R1 is: halo, -CN, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -O-C1-C6 alkyl or -SO2-C1-C6 alkyl; R2 is: H, halo, or -CN; R3, R5, and R6 are each independently: H, halo, or -O-C1-C6 alkyl; R4 is independently: halo, -CN, C1-C6 alkyl, -O-C1-C6 alkyl, C3-C6 cycloalkyl, -O-C3-C6 cycloalkyl, or -O-C1-C6 alkyl-C3-C6 cycloalkyl; wherein said C1-C6 alkyl, -O-C1-C6 alkyl, C3-C6 cycloalkyl, -O-C3-C6 cycloalkyl, and -O-C1-C6 alkyl-C3-C6 cycloalkyl, are optionally substituted with from 1 to 6 groups each independently: deuterium, -CN, halo, -O-C1-C3 alkyl, or -O-C1-C3 haloalkyl; R7 is halo, or -O-C1-C6 alkyl; X1 is CR8; and R8 is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, -O-C1-C6 alkyl, or -O-C1-C6 haloalkyl. The compounds are GPR17 modulators. Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases and conditions associated with GPR17, including multiple sclerosis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). Figure formula (I)

USE OF MICRORNAS AS TOOLS FOR THE DIAGNOSIS AND DIFFERENTIATION OF TAUOPATHIES

Resumen de: US2024368188A1

0000 6,7-Dihydrothiazolo5,4-cpyridines substituted in the 5-position with heterocyclic rings are positive allosteric modulators of the muscarinic acetylcholine receptor Ma (mAChR MA) and may have use in treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction.

REGULATE GUT MICROBIOTA TO TREAT NEURODEGENERATIVE DISORDERS

Resumen de: EP4707410A2

0001 Disclosed herein are methods and compositions that can be used to improve motor deficits and neuroinflammation in subjects in need, for example subjects suffering from neurodegenerative disorders (e.g., Parkinson's disease). Also disclosed are methods and compositions that can be used to diagnose neurodegenerative disorders, such as Parkinson's disease.

miR-937-3p PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE COMPRISING miR-937-3p INHIBITOR

Resumen de: KR20260032813A

본 발명은 알츠하이머병 예방 또는 치료용 약학 조성물에 관한 것으로서, 보다 상세하게는, miR-937-3p 억제제를 포함함으로써 신경세포의 세포사멸을 억제하여 알츠하이머병을 예방 또는 치료할 수 있는 신규한 알츠하이머병 예방 또는 치료용 약학 조성물에 관한 것이다.

miR-4536-3p PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE COMPRISING miR-4536-3p INHIBITOR

Resumen de: KR20260032816A

본 발명은 알츠하이머병 예방 또는 치료용 약학 조성물에 관한 것으로서, 보다 상세하게는, miR-4536-3p 억제제를 포함함으로써 신경세포의 세포사멸을 억제하여 알츠하이머병을 예방 또는 치료할 수 있는 신규한 알츠하이머병 예방 또는 치료용 약학 조성물에 관한 것이다.

miR-4284 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE COMPRISING miR-4284 INHIBITOR

Resumen de: KR20260032814A

본 발명은 알츠하이머병 예방 또는 치료용 약학 조성물에 관한 것으로서, 보다 상세하게는, miR-4284 억제제를 포함함으로써 신경세포의 세포사멸을 억제하여 알츠하이머병을 예방 또는 치료할 수 있는 신규한 알츠하이머병 예방 또는 치료용 약학 조성물에 관한 것이다.

- - A method for inducing the expression of a brain-derived neurotrophic factor protein or a gene encoding the same in stem cells and a pharmaceutical composition for treating or preventing Parkinson's disease comprising stem cells expressing a brain-derived neurotrophic factor protein or a gene encoding the same as an active ingredient

Nº publicación: KR20260030686A 06/03/2026

Solicitante:

가톨릭대학교산학협력단